Dendreon Corp fka DNDNQ

[i760]

"companies would not design in explicit p-value allocations for survival."

Could you provide some precedents where what you allege is true -- trials where FDA has allocated p value has been between a surrogate for an endpoint and that endpoint itself (for example a trial in which p value is allocated between a progression endpoint and survival).

Ocyan's and Clark's point is that there is no need for such allocation and Ocyan post has a link to the ODAC discussion about that topic.